Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on Induction of Remission Using Bortezomib (Vel), Cyclophosphamide (C), and Dexamethasone (D) in Patients Until 60 Years of Age With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy: (VelCD; Deutsche Studiengruppe Multiples Myelom [DSMM] XIa)

NCT00833560 is registered in ClinicalTrials.gov with Janssen-Cilag G.m.b.H as lead sponsor.

NCT NCT00833560
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00833560 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on Induction of Remission Using Bortezomib (Vel), Cyclophosphamide (C), and Dexamethasone (D) in Patients Until 60 Years of Age With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy: (VelCD; Deutsche Studiengruppe Multiples Myelom [DSMM] XIa)
Lead sponsor
Janssen-Cilag G.m.b.H
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2006
Completion date
June 30, 2009
Enrollment
401 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma